Literature DB >> 15146470

Seven novel mutations of the ADAR gene in Chinese families and sporadic patients with dyschromatosis symmetrica hereditaria (DSH).

Xue-Jun Zhang1, Ping-Ping He, Ming Li, Chun-Di He, Kai-Lin Yan, Yong Cui, Sen Yang, Kai-Yue Zhang, Min Gao, Jian-Jun Chen, Cheng-Rang Li, Lin Jin, Hong-Duo Chen, Shi-Jie Xu, Wei Huang.   

Abstract

Dyschromatosis symmetrica hereditaria (DSH) is an autosomal dominant pigmentary genodermatosis characterized by hyperpigmented and hypopigmented macules of on the extremities and caused by the mutations in the ADAR gene(also called DSRAD) encoding for RNA-specific adenosine deaminase. Here we reported clinical and molecular findings of 6 Chinese multi-generation families and 2 sporadic patients with DSH. We found that the same mutation could lead to different phenotypes even in the same family and we did not establish a clear correlation between genotypes and phenotypes. Seven novel heterozygous mutations of ADAR were identified, which were c.2433_2434delAG (p.T811fs), c.2197G>T (p.E733X), c.3286C>T (p.R1096X), c.2897G>T (p.C966F), c.2797C>T (p.Q933X), c.2375delT (p.L792fs) and c.3203-2A>G respectively. Our data add new variants to the repertoire of ADAR mutations in DSH. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146470     DOI: 10.1002/humu.9246

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

Review 1.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

Review 2.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

3.  A Fluorescent Adenosine Analogue as a Substrate for an A-to-I RNA Editing Enzyme.

Authors:  Rena A Mizrahi; Dongwon Shin; Renatus W Sinkeldam; Kelly J Phelps; Andrea Fin; Dean J Tantillo; Yitzhak Tor; Peter A Beal
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-10       Impact factor: 15.336

4.  Probing RNA recognition by human ADAR2 using a high-throughput mutagenesis method.

Authors:  Yuru Wang; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2016-09-09       Impact factor: 16.971

Review 5.  To protect and modify double-stranded RNA - the critical roles of ADARs in development, immunity and oncogenesis.

Authors:  Emily A Erdmann; Ananya Mahapatra; Priyanka Mukherjee; Boyoon Yang; Heather A Hundley
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-12-27       Impact factor: 8.250

6.  Recognition of duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2.

Authors:  Kelly J Phelps; Kiet Tran; Tristan Eifler; Anna I Erickson; Andrew J Fisher; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2015-01-06       Impact factor: 16.971

Review 7.  Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs.

Authors:  Carl R Walkley; Jin Billy Li
Journal:  Genome Biol       Date:  2017-10-30       Impact factor: 13.583

8.  Consistent levels of A-to-I RNA editing across individuals in coding sequences and non-conserved Alu repeats.

Authors:  Shoshana Greenberger; Erez Y Levanon; Nurit Paz-Yaacov; Aviv Barzilai; Michal Safran; Sivan Osenberg; Ninette Amariglio; Gideon Rechavi; Eli Eisenberg
Journal:  BMC Genomics       Date:  2010-10-28       Impact factor: 3.969

9.  Editing independent effects of ADARs on the miRNA/siRNA pathways.

Authors:  Bret S E Heale; Liam P Keegan; Leeanne McGurk; Gracjan Michlewski; James Brindle; Chloe M Stanton; Javier F Caceres; Mary A O'Connell
Journal:  EMBO J       Date:  2009-08-27       Impact factor: 11.598

10.  Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity.

Authors:  Melissa M Matthews; Justin M Thomas; Yuxuan Zheng; Kiet Tran; Kelly J Phelps; Anna I Scott; Jocelyn Havel; Andrew J Fisher; Peter A Beal
Journal:  Nat Struct Mol Biol       Date:  2016-04-11       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.